ADAMAS PHARMACEUTICALS, INC. Inactive Instrument
Adamas Pharmaceuticals, Inc. Stock
Equities
ADMS
US00548A1060
Biotechnology & Medical Research
More news
More recommendations
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Jack Khattar
PSD | President | 62 | 21-11-23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Jack Khattar
PSD | President | 62 | 21-11-23 |
| Director/Board Member | - | 21-11-23 |
Adamas Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in drug discovery, development and commercialization to deliver medicines for patients, caregivers, and society. The Company's portfolio product GOCOVRI (amantadine) extended release capsules is used for the treatment of dyskinesia in patients with Parkinson's disease. Its OSMOLEX ER (amantadine) extended-release tablets is used for the treatment for Parkinson's disease and drug-induced extrapyramidal reactions in adult patients. Its ADS-5102 is in development for the treatment of walking impairment in patients with multiple sclerosis (MSW). Its product candidate ADS-4101 (lacosamide) modified release capsules is in development for the treatment of partial onset seizures in patients with epilepsy. Its Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules are used for the treatment of dementia of an Alzheimer's type.
| 1st Jan change | Capi. | |
|---|---|---|
| +1.12% | 43.84B | |
| +6.77% | 41.68B | |
| +45.26% | 41.25B | |
| -11.96% | 27.04B | |
| +6.01% | 25.53B | |
| -24.92% | 18.18B | |
| -3.63% | 12.29B | |
| +27.16% | 12.29B | |
| +7.30% | 11.15B |
